Aclarion Outlines 2026 Strategy with Focus on Reimbursement and Clinical Trial Milestones

Aclarion, Inc. has published a shareholder letter from CEO Brent Ness highlighting the company's strategic progress and key priorities for 2026, focusing on expanding adoption of its Nociscan platform for chronic low back pain diagnosis. The letter emphasizes momentum in clinical evidence generation, commercial engagement, and reimbursement initiatives in both the United Kingdom and United States markets. According to Ness, the company's focus remains on disciplined execution against catalysts that could expand Nociscan adoption and strengthen the clinical and reimbursement foundation of the business.

The company is pursuing reimbursement coverage from regional insurance providers in the United States as an important step toward broader payer adoption. This initiative represents a critical component of Aclarion's strategy to increase accessibility to its technology platform. The Nociscan platform utilizes magnetic resonance spectroscopy, proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to help physicians distinguish between painful and nonpainful discs in the lumbar spine. When used with other diagnostic tools, the technology provides insights into the location of a patient's low back pain, potentially optimizing treatment strategies.

A significant catalyst highlighted in the letter is the initial readout from the ongoing CLARITY clinical trial expected in the fourth quarter of 2026. This trial represents an important component of the company's evidence generation strategy and could provide additional validation for the Nociscan technology. The company's strong balance sheet with cash runway into 2028 supports continued execution of these strategic priorities without immediate financial constraints. Additional information about the company's technology and approach is available on their website at https://www.aclarion.com.

The shareholder letter underscores Aclarion's position as it advances its mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders. With increasing physician engagement, growing clinical evidence, and continued progress with payers, the company believes it is well positioned for the coming year. The full CEO Shareholder Letter is available on the company's website, providing investors and stakeholders with detailed insights into the strategic direction. For those seeking to locate Nociscan centers, the company provides a site map through their online resources.